Imaging Agents Archives - MPR

Imaging Agents

Lumason Approved for Pediatric Patients With Suboptimal Echocardiograms

The Food and Drug Administration (FDA) has approved Lumason (sulfur hexafluoride lipid-type A microspheres; Bracco Diagnostics Inc.), an ultrasound enhancing agent, for use in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in pediatric patients with suboptimal echocardiograms. Previously, the treatment was only approved for…

Varibar Thin Liquid Gets FDA Approval for Modified Barium Swallow Studies

The Food and Drug Administration (FDA) has approved Varibar Thin Liquid for oral suspension (barium sulfate; Bracco Diagnostics Inc.) for use in modified barium swallow (MBS) examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients. Varibar Thin Liquid is a radiographic contrast agent that is supplied as a powder…

Contrast Agent Gadavist Approved for Use in Cardiac MRI

The Food and Drug Administration (FDA) has approved Gadavist (gadobutrol; Bayer) injection for use in cardiac magnetic resonance imaging (MRI) to assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD). The approval was based on data from two phase 3 multicenter, open-label trials that…